Elevance Health Beats Third-Quarter Forecasts and Raises Guidance, but a $1.85 Non-Operating Benefit Flatters the Beat

A health insurer's quarter is really two stories — the medical costs it controlled and the investment gains it did not — and Elevance Health's third quarter told both at once.

Elevance Health reported third-quarter results on Wednesday, Oct. 21, with operating revenue of $50.44 billion, up 0.7% from a year earlier, and adjusted diluted earnings of $6.99 a share. The earnings figure beat the consensus estimate of $4.71 a share, and revenue came in ahead of forecasts of $49.22 billion, according to the FactSet consensus reported by Barron's. The company said the earnings figure reflected a net non-operating benefit of $1.85 a share and about $0.50 a share of operating outperformance.

The beat needs its asterisk

The gap between the headline beat and the operating business is the quarter in one line. Diluted earnings were $6.27 a share, up from $5.32 a year earlier, adjusted diluted earnings were $6.99, up from $6.03, and shareholders' net income rose to $1.37 billion from $1.19 billion — but operating gain was flat at $1.3 billion, and adjusted operating gain was flat as well, with the operating margin easing to 2.5% from 2.6%. Net investment income jumped to $1.04 billion in the quarter. In other words, Elevance genuinely outperformed on operations by roughly half a dollar a share, and the rest of the distance past consensus arrived through non-operating items that say little about next quarter's medical costs.

That distinction matters because Elevance kept the non-operating benefit inside its own headline disclosure rather than burying it — the release itself states that results reflect a net non-operating benefit of $1.85 per share. Readers should price the quarter as a solid operating beat with a large, disclosed tailwind, not as evidence that the underlying insurance engine suddenly earned $2.28 a share more than Wall Street expected.

Medical costs improved where it mattered most

The operating evidence that does repeat is medical-cost control. The benefit expense ratio was 90.6%, an improvement of 70 basis points from a year earlier, driven by better performance in Medicare Advantage and the individual Affordable Care Act business, and it came in below the consensus estimate of 91.1%. Days in Claims Payable stood at 44.9 days, up 3.5 days year over year. The cost of that progress showed up on the expense line instead: the operating expense ratio was 11.4%, and the adjusted operating expense ratio was 11.3%, up 90 basis points from a year earlier, principally reflecting targeted one-time investments in capabilities and spending to advance growth and quality initiatives.

Carelon carried the segments while Health Benefits slipped

By segment, the services arm did the lifting. Health Benefits operating revenue was $43.4 billion, up 3% on higher premium yields and service fee revenue, partly offset by lower Medicare Advantage, Medicaid and Employer Group risk membership — but Health Benefits operating gain fell to $400 million from $600 million a year earlier, a decline the company tied to targeted investments, with the segment margin narrowing to 1.0% from 1.4%. Carelon moved the other way: operating revenue rose 5% to $19.3 billion on CarelonRx product revenue and expansion of Carelon Services risk-based solutions, operating gain rose 17% to $900 million, and the Carelon margin widened to 4.7% from 4.2%.

Membership explains the tension. Medical membership was about 44.9 million at Sept. 30, down 487,000 from a year earlier, as Medicare Advantage membership fell 15.5% to 1,898,000 and Medicaid membership fell 4.9% to 8,220,000, partly offset by growth in commercial fee-based membership. Elevance is deliberately smaller in the government books it reshaped for 2026 — the open question is whether the smaller book earns enough to replace the members it shed.

The raise is the durable part of the print

Guidance is where the quarter outlasts its asterisk. Elevance raised its full-year 2026 outlook to diluted earnings of at least $22.00 a share and adjusted diluted earnings of at least $29.00 a share, up from prior guidance of at least $27, and raised its operating cash flow outlook to at least $6.5 billion. The company also lifted its earnings baseline to at least $26.75 a share, up $0.75, and said it remains confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from that baseline, which excludes non-recurring net investment income and other non-operating items as well as targeted one-time investments. Operating cash flow was $1.3 billion in the quarter, the company repurchased 800,000 shares for $330 million at a weighted average price of $398.75, and it declared a fourth-quarter dividend of $1.72 a share, payable Dec. 18 to shareholders of record on Dec. 4. The shares had gained 25.6% year to date through Tuesday's close at $440.18, so the raise — not the flattered beat — is the part of the print the stock had not already paid for.

What to watch from here

Three tests decide whether this quarter compounds. First, whether the roughly $0.50 a share of operating outperformance repeats without non-operating help. Second, whether Health Benefits can rebuild its margin from 1.0% while Medicare Advantage works toward the company's target of at least 2% this year and Medicaid works through what the company has called a trough year, with a full-year Medicaid operating margin outlook of -1.75% and early signs of slight improvement relative to expectations. Third, whether the targeted one-time investments that lifted the expense ratio start paying back in growth and quality, as management intends. Management discusses the results and outlook on its conference call today at 8:30 a.m. Eastern.